Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Got NGF? Promising gene therapy results in Alzheimer's disease

Got NGF? Promising gene therapy results in Alzheimer's disease Tuszynski MH, Thal L, Pay M et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005: 6: 551–5. Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the most common form of senile dementia. It is characterized by gradual memory loss that begins during the early stages of the disease. As the disease progresses, deterioration of higher cortical function (confusion and disorientation) and behavioral disturbances (depression, agitation, and delusion) occur, eventually leaving affected individuals unable to care for themselves. The primary neuropathological hallmarks of AD consist of extracellular plaques of aggregated ॆ-amyloid protein, intracellular neurofibrillary tangles containing hyper-phosphorylated tau protein, and progressive loss of cortical and subcortical neurons. Selective degeneration of the cholinergic neurons of the nucleus basalis is one of the earliest pathological events in AD ( 1 ). To date, only symptomatic therapeutic agents have been approved for the treatment of AD, such as the acetyl-cholinesterase inhibitors and the non-competitive N-Methyl-d-Aspartate (NMDA)-receptor antagonist memantine. Disease-altering treatments that prevent neuronal loss and/or enhance neuronal function are desperately needed. Ex vivo gene therapy is one such novel therapeutic approach in which autologous cells are genetically modified in vitro http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Genetics Wiley

Got NGF? Promising gene therapy results in Alzheimer's disease

Clinical Genetics , Volume 68 (3) – Sep 1, 2005

Loading next page...
 
/lp/wiley/got-ngf-promising-gene-therapy-results-in-alzheimer-s-disease-AMWrf8QjjE

References (2)

Publisher
Wiley
Copyright
Blackwell Munksgaard, 2005
ISSN
0009-9163
eISSN
1399-0004
DOI
10.1111/j.1399-0004.2005.0494b.x
Publisher site
See Article on Publisher Site

Abstract

Tuszynski MH, Thal L, Pay M et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005: 6: 551–5. Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the most common form of senile dementia. It is characterized by gradual memory loss that begins during the early stages of the disease. As the disease progresses, deterioration of higher cortical function (confusion and disorientation) and behavioral disturbances (depression, agitation, and delusion) occur, eventually leaving affected individuals unable to care for themselves. The primary neuropathological hallmarks of AD consist of extracellular plaques of aggregated ॆ-amyloid protein, intracellular neurofibrillary tangles containing hyper-phosphorylated tau protein, and progressive loss of cortical and subcortical neurons. Selective degeneration of the cholinergic neurons of the nucleus basalis is one of the earliest pathological events in AD ( 1 ). To date, only symptomatic therapeutic agents have been approved for the treatment of AD, such as the acetyl-cholinesterase inhibitors and the non-competitive N-Methyl-d-Aspartate (NMDA)-receptor antagonist memantine. Disease-altering treatments that prevent neuronal loss and/or enhance neuronal function are desperately needed. Ex vivo gene therapy is one such novel therapeutic approach in which autologous cells are genetically modified in vitro

Journal

Clinical GeneticsWiley

Published: Sep 1, 2005

There are no references for this article.